Continuous Glucose Monitoring System Improves Glycemic Management and Patient Outcomes in Hospital Setting
By HospiMedica International staff writers Posted on 04 Mar 2022 |
A new real-time continuous glucose monitoring (CGM) system for people with diabetes has the potential for more effective glycemic management and improved patient outcomes in the hospital setting. Advances in CGM have transformed ambulatory diabetes management. Until recently, inpatient use of CGM has remained investigational, with limited data on its accuracy in the hospital setting. Several studies have indicated that CGM technology is a reliable tool for hospital use and may help improve glucose monitoring in non–critically ill hospitalized patients with diabetes.
DexCom, Inc.’s (San Diego, CA, USA) CGM system uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device, providing real-time glucose data without the need for fingersticks. The system also offers customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events. Dexcom CGM has been granted Breakthrough Device Designation by the FDA for use in the hospital setting, marking a critical milestone for its in-patient use. The designation provides a more efficient and streamlined review pathway so innovative Dexcom CGM technology can get to the hospital market faster.
“In our extensive use of Dexcom CGM in our hospitals as part of exploratory studies over the last seven years, more than 800 of those patients treated during the pandemic, we have found that the device improves glucose control without any increased risk in hypoglycemia,” said Athena Philis-Tsimikas, M.D., endocrinologist and corporate vice president for the Scripps Whittier Diabetes Institute. “Breakthrough Device Designation from the FDA could be transformative for using CGM for in-patient care in hospitals.”
“During the COVID-19 pandemic, the FDA allowed Dexcom CGM to be used in hospitals to help health care providers manage patient glucose levels,” said Gil Rivas, vice president, general manager of hospital at Dexcom. “What started as a response during the pandemic has shown promise as a better alternative to fingerstick blood glucose tests with greater quality of care and patient satisfaction.”
Related Links:
DexCom, Inc.
Latest Critical Care News
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events
- AI Diagnostic Tool Guides Rapid Diagnosis and Prediction of Sepsis
- World's First AI-Powered Sepsis Alert System Detects Sepsis in One Minute
- Smartphone Magnetometer Uses Magnetized Hydrogel to Measure Biomarkers for Disease Diagnosis
- New Technology to Revolutionize Valvular Heart Disease Care